COMMUNIQUÉS West-GlobeNewswire

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
28/02/2024
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“ [...]
Inari Medical Reports Fourth Quarter 2023 Financial Results
28/02/2024
IRVINE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28/02/2024
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in [...]
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28/02/2024
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected [...]
RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
28/02/2024
ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported [...]
Merit Medical Introduces “Continued Growth Initiatives” Program and Financial Targets for Three-Year Period Ending December 31, 2026
28/02/2024
SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives [...]
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
28/02/2024
Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024 Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024 [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
28/02/2024
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024 Received Orphan Drug Designation for LYL845 for the treatment of melanoma Expect to submit IND for [...]
Merit Medical Reports Results For Fourth Quarter and Year Ended December 31, 2023 - Issues Fiscal Year 2024 Guidance
28/02/2024
Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-year Q4 2023 constant currency revenue* up 10.3% year-over-year Q4 2023 constant currency revenue, organic* up 8.3% year-over-year Q4 2023 GAAP operating [...]
Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
28/02/2024
SUNNYVALE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three [...]
Pennant Reports Fourth Quarter and Fiscal Year 2023 Results
28/02/2024
Conference Call and Webcast scheduled for tomorrow, February 29, 2024 at 10:00 am MT EAGLE, Idaho, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28/02/2024
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA ( 1 ) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ( 2 ) of $8.5 Million [...]
WW International, Inc. Announces Upcoming Oprah Winfrey Board Transition
28/02/2024
Continued Collaboration to Advocate for and Elevate Conversation on Weight Health Ms. Winfrey to Donate Financial Interest in WeightWatchers to the National Museum of African American History and Culture NEW YORK, Feb. [...]
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
28/02/2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance [...]
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
28/02/2024
Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory [...]
WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results
28/02/2024
Fourth Quarter 2023 End of Period Subscribers of 3.8 million, including 67 thousand End of Period Clinical Subscribers Revenues of $206.0 million Gross margin of 60.6%; excluding the net impact of restructuring charges [...]
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
28/02/2024
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28/02/2024
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28/02/2024
- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash position and [...]

Pages